| Identification | Back Directory | [Name]
1H-Pyrazole-1-carboximidamide, 3-(4-chlorophenyl)-4,5-dihydro-N'-(1-iminoethyl)-4-phenyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4S)- | [CAS]
1998760-00-1 | [Synonyms]
(S)-MRI-1867
Zevaquenabant
1H-Pyrazole-1-carboximidamide, 3-(4-chlorophenyl)-4,5-dihydro-N'-(1-iminoethyl)-4-phenyl-N-[[4-(trifluoromethyl)phenyl]sulfonyl]-, (4S)- | [Molecular Formula]
C25H21ClF3N5O2S | [MOL File]
1998760-00-1.mol | [Molecular Weight]
547.98 |
| Hazard Information | Back Directory | [Uses]
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD)[1]. | [in vivo]
Zevaquenabant (3 mg/kg; p.o.; for 28 days) improves renal morphological and functional parameters in diet-induced obese mice[1]. | Animal Model: | 6-week-old male C57Bl/6J mice (diet-induced obesity)[1] | | Dosage: | 3 mg/kg | | Administration: | P.o.; for 28 days | | Result: | Improved kidney morphology and function in diet-induced obese mice.
|
| [IC 50]
CB1 | [References]
[1] Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178(5):1250]. Br J Pharmacol. 2020;177(1):110-127. DOI:10.1111/bph.14849 |
|
|